Liquid Biopsies for Cancer: A Translational Science Review.
Blood tests detecting tumor DNA fragments catch cancer relapse months earlier than imaging, offering patients precious time for intervention.
This JAMA translational review comprehensively covers ctDNA clinical applications including treatment response monitoring, minimal residual disease detection, and resistance mutation identification across NSCLC, CRC, and breast cancer. Key evidence includes a 1,725-patient urothelial carcinoma meta-analysis (HR for DFS 20.69 with high ctDNA) and a prospective CRC cohort showing 8.7-month earlier molecular relapse detection versus standard imaging.
What the study was
- Study design
- Translational Science Review
- Population
- Cancer patients across multiple tumor types undergoing ctDNA-based evaluation
- Category
- Early Detection
- Maturity
- Potentially Practice-Changing
- Journal
- JAMA
Why it surfaced
High-impact JAMA translational review synthesizing ctDNA clinical utility with cited prospective evidence; directly actionable for pipeline on liquid biopsy implementation and evidence gaps.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.